Drug Profile
Research programme: cardiac cell reprogramming - LoneStar Heart
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer LoneStar Heart
- Class Cell therapies; Ischaemic heart disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route) (https://pitchbook.com/profiles/company/42705-73#overview)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in USA
- 02 Aug 2016 Preclinical trials in Ischaemic heart disorders in USA (unspecified route)